EUCTR2004-004796-11-DE进行中（未招募）不适用
An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy
Klinikum Augsburg0 个研究点目标入组 100 人开始时间: 2007年1月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients must fulfill all of these inclusion criteria:
- •1. Signed written informed consent.
- •2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 – 2
- •3. Postmenopausal status defined by one of the following:
- •Age >/= 55 years with cessation of menses.
- •Age <55 but no spontaneous menses for at least 1 year.
- •Age <55 and spontaneous menses within the past 1 year, but currently amenorrheic (e.g., spontaneous, or secondary to hysterectomy), and with postmenopausal gonadotrophin levels (luteinizing hormone and follicle stimulating hormone levels >40 IU/L) or postmenopausal estradiol levels (<5ng/dL) or according to the definition of postmenopausal range” for the laboratory involved.
- •Bilateral oophorectomy.
- •4. Hormone receptor positive defined as ER and/or PgR >/= 2 (Remmele/Stegner)
- •5. Patients with a baseline lumbar spine BMD T-score at or above - 2.0 SD.
- •6. Adequately diagnosed and treated invasive breast cancer defined as:
- •Patients with invasive breast cancer whose tumor can be removed by an appropriate surgical procedure such as mastectomy or breast conserving surgery and who receive, if appropriate, additional local (e.g. radiotherapy) and/or systemic (i.e. adjuvant chemotherapy) treatments, according to best practice.
- •Patients may have also received prior neoadjuvant chemotherapy. Prior neoadjuvant chemotherapy must be completed before entering the patient onto the present protocol.
- •The date of registration must be no more than:
- •a. 4 weeks from completion of surgery (in case of surgery alone), or
- •b. 4 weeks from completion of surgery (in case of surgery + radiotherapy) or
- •c. 4 weeks after completion of adjuvant chemotherapy (if planned to be given before the endocrine therapy) or
- •d. 4 weeks after completion of chemotherapy followed by radiation.
- •Completion of chemotherapy is defined as completion of the last full course including recovery time.
- •When the plan is to give concomitant adjuvant chemotherapy and hormonotherapy, the treatment should start at the same time and the date of registration must be no more than 4 weeks from completion of surgery;
- •Patients must have no clinical or radiological evidence of distant metastasis, and no other concomitant malignancy.
- •7. Patients must be able to swallow the study medication and have adequate unassisted oral intake to maintain a reasonable state of nutrition.
- •8. Life expectancy of at least 12 months from registration.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with any clinical or radiological evidence of distant spread of their disease at any point before registration.
- •2. Patients with invasive bilateral breast cancer.
- •3. Patients with any clinical or radiological evidence of existing fracture in the lumbar spine and/or total hip.
- •4. Patients with a history of fracture with low-density or no associated trauma.
- •5. Patients who have started adjuvant hormonal therapy or who have completed adjuvant hormonal therapy prior to registration.
- •6. Patients who have received any endocrine therapy within the past 12 months (other than neoadjuvant tamoxifen or torimefene, insulin and/or anti-diabetic medications, and thyroid hormone replacement). Hormone replacement therapy must be discontinued at least 4 weeks prior to registration.
- •7. Patients currently receiving oral bisphosphonates. Oral bisphosphonates must be discontinued within 3 weeks of baseline evaluations.
- •8. Patients who have received prior treatment with systemic corticosteroids within the past 12 months (short term corticosteroid therapy, e.g. to prevent/treat chemotherapy-induced nausea/vomiting is allowed).
- •9. Patients with prior exposure to anabolic steroids or growth hormone within the past 6 months.
- •10. Treatment with tibolone must be discontinued at least 4 weeks prior to registration.
- •11. Any prior use of parathyroid hormone (PTH) for more than 1 week.
- •12. Prior use of systemic sodium fluoride for > 3 months during the past 2 years.
- •13. Patients currently treated with any drugs known to affect the skeleton (e.g., calcitonin, mithramycin, or gallium nitrate) within 2 weeks prior to registration.
- •14. Patients with previous or concomitant malignancy (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease-free for five years.
- •15. Patients with other non-malignant systemic diseases including uncontrolled infections, uncontrolled type 2 diabetes mellitus, uncontrolled thyroid dysfunction, cardiovascular, renal, hepatic, and lung diseases which would prevent prolonged follow-up. Patients with previous history of thrombosis or thromboembolism can be included only if suitable for prolonged follow-up and not on steroids. Patients with a known history of HIV are excluded.
- •16. A calculated creatinine clearance < 30 ml/minute.
- •Creatinine clearance (CrCl) is calculated using the Cockcroft-Gault formula:
- •CrCl= [140-age (years)] x weight (kg) {x 0.85 for female patients}
- •-------------------------------------------
- •[72 x serum creatinine (mg/dL)]
- •17. Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
- •18. Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants).
- •19. History of diseases with influence on bone metabolism, such as Paget’s disease, Osteo-genesis Imperfecta, and primary or secondary hyperthyroidism within the 12 months prior to study entry.
- •20. Patients with baseline lumbar spine BMD T-score below –2.0 SD.
- •21. Known hypersensitivity to zoledronic acid or other bisphosphonates.
- •22. Mental illness that precludes the patient from giving informed consent.
- •23. WBC </
研究者
相似试验
尚未招募
不适用
An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients with Advanced Solid Tumors or Lymphomas, who are Unsuitable For, or Have Failed, Existing TherapiesDrug Metabolism10027656CancerNL-OMON33844Eisai10
尚未招募
不适用
An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of Carbon-14 labeled Eribulin Acetate (14C-Eribulin) in Patients with Advanced Solid TumorsDrug metabolism10027656CancerNL-OMON32470Eisai10
进行中（未招募）
不适用
A study comparing cholic acid capsules that are not currently available, with cholic acid capsules that are currently available, to check that they are as safe and work just as well in treating children born with a birth defect inherited from their parents, which means that their body cannot make normal bile acidsPatients with inborn errors of bile acid synthesis and metabolismMedDRA version: 14.0Level: PTClassification code 10070882Term: Inborn error in primary bile acid synthesisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004491-10-Outside-EU/EEAAsklepion Pharmaceuticals, LLC16
已完成
不适用
Single-center, open-label, non-randomized study investigating the excretion balance, pharmacokinetics and metabolism of a single oral dose of [14C]-labeled RO5285119 in healthy male subjectsAutism Disorder10029305ASDAsperger's syndromeNL-OMON41196F. Hoffmann-La Roche Ltd6
进行中（未招募）
1 期
A clinical study exploring the use of rFVIIIFc in patients with severe Haemophilia A who are undergoing Immune Tolerance Induction (ITI) for the first timeMedDRA version: 20.0 Level: LLT Classification code 10060613 Term: Hemophilia A (Factor VIII) System Organ Class: 100000011915MedDRA version: 20.0 Level: LLT Classification code 10053751 Term: Hemophilia A with anti factor VIII System Organ Class: 100000011928Hemophilia AEUCTR2017-000373-36-GBBioverativ Therapeutics Inc.30